MTOR and Ewing sarcoma: We applied these criteria to selected potential agents of greatest interest (Table 2).Table 2 also provides a benchmark for ganitumab, an agent currently in phase 3 testing in newly diagnosed metastatic ES, and for mammalian target of rapamycin (mTOR) inhibitors currently proposed for the next COG trial for first recurrence.